Costs and Health Resources Utilization Following Switching to Pregabalin in Individuals with Gabapentin-Refractory Neuropathic Pain: A post hoc Analysis.
In: Pain Practice, Jg. 12 (2012-06-01), Heft 5, S. 382-393
Online
academicJournal
Zugriff:
Purpose: To analyze the changes in pain severity and associated costs resulting from resource utilization and reduced productivity in patients with gabapentin-refractory peripheral neuropathic pain who switched to pregabalin therapy in primary care settings in Spain. Patients and Methods: This is a post hoc analysis of a 12-week, multicentre, noninterventional cost-of-illness study. Patients were included in the study if they were over 18 years of age and had a diagnosis of chronic, treatment-refractory peripheral neuropathic pain. The analysis included all pregabalin-naïve patients who had previously shown an inadequate response to gabapentin and switched to pregabalin. Severity of pain before and after treatment with pregabalin, alone or as an add-on therapy, was assessed using the Short-Form McGill Pain Questionnaire (SF-MPQ) and its related visual analogue scale (VA). Healthcare resource utilization, productivity (including lost-workday equivalents [LWDE]), and related costs were assessed at baseline and after pregabalin treatment. Results: A total of 174 patients switched to pregabalin had significant and clinically relevant reductions in pain severity (mean [SD] change on SF-MPQ VA scale, −31.9 [22.1]; P < 0.05 vs. baseline; effect size, 1.87). Reduction in pain was similar with both pregabalin monotherapy and add-on therapy. Significant reductions in healthcare resource utilization (concomitant drug use [in pregabalin add-on group], ancillary tests, and unscheduled medical visits) were observed at the end of trial. Additionally, there were substantial improvements in productivity, including a reduction in the number of LWDE following pregabalin treatment (−18.9 [26.0]; P < 0.0001). These changes correlated with substantial reductions in both direct (−652.9 ± 1622.4 €; P < 0.0001) and indirect healthcare costs (−851.6 [1259.6] €; P < 0.0001). Conclusions: The cost of care in patients with gabapentin-refractory peripheral neuropathic pain appeared to be significantly reduced after switching to pregabalin treatment, alone or in combination with other analgesic drugs, in a real-life setting. [ABSTRACT FROM AUTHOR]
Titel: |
Costs and Health Resources Utilization Following Switching to Pregabalin in Individuals with Gabapentin-Refractory Neuropathic Pain: A post hoc Analysis.
|
---|---|
Autor/in / Beteiligte Person: | Navarro, Ana ; Saldaña, María T. ; Pérez, Concepción ; Masramón, Xavier ; Rejas, Javier |
Link: | |
Zeitschrift: | Pain Practice, Jg. 12 (2012-06-01), Heft 5, S. 382-393 |
Veröffentlichung: | 2012 |
Medientyp: | academicJournal |
ISSN: | 1530-7085 (print) |
DOI: | 10.1111/j.1533-2500.2011.00515.x |
Schlagwort: |
|
Sonstiges: |
|